Reduced vs standard GVHD prevention in stem cell transplant
Part of Immune system & allergy clinical trials.
This trial tests whether a lower dose of a common drug (cyclophosphamide) after transplant can prevent graft-versus-host disease (a complication where donor cells attack your body) just as well as the standard dose. It also uses another medicine (anti-thymocyte globulin) after the transplant to help protect you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting a stem cell transplant from a matched unrelated donor or a half-matched (haplo-identical) donor.
- Your kidneys, liver, lungs, and heart are working normally.
- You are able to care for yourself and do light activities (ECOG score 0-2).
- You are expected to live at least 3 more months.
- You are not pregnant, and you do not have active hepatitis B, active infections needing antibiotics, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests a new way to prevent graft-versus-host disease (GVHD) after a stem cell transplant in people who have already received PD-1 immunotherapy. The goal is to make the transplant safer and more effective.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This trial tests a new drug, BPC2001, to see if it can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) in people receiving a half-matched stem cell transplant from a family donor. It may be an option for adults with certain blood cancers who are planning their first transplant.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
Hear when a new Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.